SignatureFD
AQST icon

SignatureFD’s Aquestive Therapeutics AQST Stock Holding History

SignatureFD’s Portfolio AQST Stock Details AQST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$9.26K Hold
2,000
– – ﹤0.01% 2754
2026
Q2 		$8.32K Hold
2,000
– – ﹤0.01% 2705
2026
Q1 		$8.3K Sell
2,000
-93
-4% -$377 ﹤0.01% 2584
2025
Q4 		$13.5K Buy
+2,093
New +$13K ﹤0.01% 2297

Other funds holding AQST

BCM
Bratton Capital Management Fort Worth, Texas $45.4M AUM 17.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $500B AUM 36.84% 1-Year Est. Return
Commonwealth Equity Services
Commonwealth Equity Services Waltham, Massachusetts $77B AUM 19.24% 1-Year Est. Return
Wasatch Advisors
Wasatch Advisors Salt Lake City, Utah $13.5B AUM 16.58% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return
Simplify Asset Management
Simplify Asset Management Las Vegas, Nevada $6.11B AUM 3.71% 1-Year Est. Return
Profund Advisors
Profund Advisors Bethesda, Maryland $3.48B AUM 66.96% 1-Year Est. Return
Citigroup
Citigroup New York $308B AUM 40.94% 1-Year Est. Return
PNC Financial Services Group
PNC Financial Services Group Pittsburgh, Pennsylvania $191B AUM 30.51% 1-Year Est. Return

SignatureFD's AQST Position: Q3 2026 in Review

SignatureFD held its Aquestive Therapeutics (AQST) position steady in Q3 2026 at 2,000 shares worth $9.26K. The position accounts for ﹤0.01% of the portfolio, ranked #2754.

SignatureFD first reported a position in AQST in Q4 2025 and has held it in 4 quarters since. The position peaked at $13.5K in Q4 2025. 74 funds tracked by Wall St. Rank hold AQST as of Q3 2026.

  • SignatureFD held 2,000 shares of Aquestive Therapeutics worth $9.26K as of Q3 2026.
  • SignatureFD left its Aquestive Therapeutics share count unchanged in Q3 2026.
  • Aquestive Therapeutics made up ﹤0.01% of SignatureFD's portfolio in Q3 2026, its #2754 holding.
  • SignatureFD first reported a position in Aquestive Therapeutics in Q4 2025 and has held it in 4 quarters since.
  • SignatureFD's Aquestive Therapeutics position peaked at $13.5K in Q4 2025.
  • 74 funds tracked by Wall St. Rank held Aquestive Therapeutics as of Q3 2026.

Based on SignatureFD's 13F filing for Q3 2026, filed 23 Oct 2026.